WO2006010189A1 - Verfahren zur reindarstellungvon kristallformen von torsemid - Google Patents
Verfahren zur reindarstellungvon kristallformen von torsemid Download PDFInfo
- Publication number
- WO2006010189A1 WO2006010189A1 PCT/AT2005/000299 AT2005000299W WO2006010189A1 WO 2006010189 A1 WO2006010189 A1 WO 2006010189A1 AT 2005000299 W AT2005000299 W AT 2005000299W WO 2006010189 A1 WO2006010189 A1 WO 2006010189A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- crystals
- torsemide
- preparation
- ethanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Definitions
- the invention relates to a process for Reindar ⁇ position of the crystal form 1 of polymorphic crystalline Torsemid, in which Torsemid is dissolved in an ethanol-water mixture with heating, whereupon subsequently cooled and dried after separation of the crystals.
- Torsemide (1-isopropyl-3- [(4-m-toluidino-3-pyridyl) sulfonyl] urea, also described in the literature as torasemide, is a known compound with interesting pharmacological properties Therefore, the active ingredient is advantageously used in the production of pharmaceutical preparations which are to be administered as diuretics.
- torasemide exists in various crystal forms. Dupont, L., Campestone, H., Lamotte, J. & Vermeire, M. (1978) Structure of a seconde variete de Ia torasemide, Acta Cryst. B34, pages 2659 to 2662 it can be seen that torasemide can be present in at least two crystal forms, which differ from one another by X-ray crystallography. The two crystal forms arise according to this reference next to each other, if a solution of torasemide in petroleum ether ethanol is evaporated. In the crystallographic distinction, a crystal form 1 was described which crystallizes monoclinically in the space group P2 ⁇ / c.
- crystal form 2 Another crystal form, which was designated as crystal form 2, crystallizes monoclinically in the space group P2 / n.
- the crystallographic data for elementary cells in both cases gave measured values of ⁇ and ⁇ of 90 °.
- the crystal form 1 was determined to have an angle ⁇ of 107 °, whereas the crystal form 2 gave an angle ⁇ of the unit cells of almost 109 °.
- the edge lengths of the unit cells could be clearly differentiated from each other. The two forms of crystallization are thus clearly distinguishable from each other, as has also been described in the literature.
- crystal form 1 or 2 and modification 1 or 2 are not necessarily synonymous, as described in Rollinger, Judith Maria et al., "Crystal forms of torasemide: new insights” Europ. of Phrmaceutics and Biopharmaceutics 53 (2002) 75-85.
- the invention now aims to provide a Ver ⁇ drive, with which it It is possible, under particularly mild conditions, to produce torsemide of the crystal form 1 in high purity, avoiding impurities such as, for example, the carbamates or decomposition products resulting from prolonged thermal stress.
- the process according to the invention consists essentially in the fact that the drying is carried out under simultaneous mechanical loading of the crystals, for example in a paddle dryer, wherein crystals of the crystal form 2 are transferred to the crystal form 1.
- the separated crystals which are mostly crystals of the crystal form 2 or represent mixtures of the crystals 2 and 1, are now dried under simultaneous mechanical loading of the crystals.
- This mechanical stress on the crystals during drying now leads to a rearrangement of the crystals of the crystal form 2 in crystals of the crystal form 1 and overall to a final product with substantially greater purity than by direct production of the crystal form I without the detour via the preparation of the crystal form 2 would be possible.
- This is substantially further improved if, as proposed according to a preferred procedure, before the formation of the pure crystal form 2, ie before the crystallization, a mechanical solids separation, in particular filtration vor ⁇ is taken.
- the inventively proposed pure production of the crystal form 2 leads to the corresponding mechanical stress in the further drying to a rearrangement in the crystal form 1, with regard to the previously shown purely pure crystal form 2 in this rearrangement directly not otherwise achievable purity of the recrystallized or rearranged to the pure crystal form 1 crystals of torasemide is achieved.
- the process according to the invention advantageously becomes so is carried out such that the heating is carried out at temperatures up to the reflux temperature over a period of less than 30 minutes, preferably 10 to 20 minutes. It is thus achieved a total solution by the choice of an ethanol-water mixture with the appropriate suitability torsemide at much shorter times and thus set the thermal load herab ⁇ significantly.
- mixtures in which ethanol and water have a mass ratio of 55:45 (volume ratio about 60:40) with a maximum deviation of the respective proportions from one to the other have proven to be particularly advantageous as ethanol-water mixture 15% by mass.
- Such ethanol-water mixtures presumably lead to the formation of Chlatraten and allow crystallization of exceedingly pure crystals of the crystal form 2 of Torsemids.
- the limitation of the solution process carried out at elevated temperature to 10 to 20 minutes represents a particularly gentle treatment, where appropriate, insoluble decomposition products or even torsemide of the crystal form 1, which dissolves relatively poorly, can be separated before seeding with seed crystals of pure crystal form 2.
- the process according to the invention is carried out in such a way that, for the preparation of the pure crystal form 2, cooling takes place with a temperature gradient of 0.2 to 1 ° C./min, preferably 0.4 ° / min to 0.6 ° / min Temperatures below 40 ° C, preferably about 20 ° C, made, whereby the thermal load can be further reduced.
- the preparation of the pure crystal form 2 of the torsemide is preferably proceeded so that immediately before or when reaching the saturation temperature, in particular between 70 ° and 60 ° C, on cooling the solution seed crystals of the crystal form 2 are added, wherein, as already mentioned, with Advantage before the addition of the seed crystals, a mechanical solids separation, in particular filtration, is made. After separation of the crystals from the liquid phase, drying under subatmospheric pressure can be carried out, thereby avoiding further thermal stresses.
- the drying was carried out in a paddle dryer.
- the mechanical stress in the drying at 40 0 C to 80 ° C resulted in complete conversion to the crystal form 1, wherein crystallographically the amount of crystal form 2 was below the detection limit.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/658,514 US20070260068A1 (en) | 2004-07-28 | 2005-07-28 | Method for the Preparation of Crystal Forms of Torsemide in a Pure State |
JP2007522871A JP2008507568A (ja) | 2004-07-28 | 2005-07-28 | トルセミドの結晶形の純粋状態での製造方法 |
EP05763057A EP1773778A1 (de) | 2004-07-28 | 2005-07-28 | Verfahren zur reindarstellung von kristallformen von torsemid |
CA002575283A CA2575283A1 (en) | 2004-07-28 | 2005-07-28 | Method for the preparation of crystal forms of torsemide in a pure state |
AU2005266828A AU2005266828A1 (en) | 2004-07-28 | 2005-07-28 | Method for the preparation of crystal forms of torsemide in a pure state |
MX2007001074A MX2007001074A (es) | 2004-07-28 | 2005-07-28 | Metodo para la preparacion de formas de cristal de torsemida en estado puro. |
NO20070856A NO20070856L (no) | 2004-07-28 | 2007-02-14 | Fremgangsmate for fremstilling av krystallformer av torsemid i ren tilstand. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0129304A AT500576B1 (de) | 2004-07-28 | 2004-07-28 | Verfahren zur reindarstellung von kristallformen von torsemid |
ATA1293/2004 | 2004-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006010189A1 true WO2006010189A1 (de) | 2006-02-02 |
Family
ID=35106999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT2005/000299 WO2006010189A1 (de) | 2004-07-28 | 2005-07-28 | Verfahren zur reindarstellungvon kristallformen von torsemid |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070260068A1 (de) |
EP (1) | EP1773778A1 (de) |
JP (1) | JP2008507568A (de) |
CN (1) | CN101056856A (de) |
AT (1) | AT500576B1 (de) |
AU (1) | AU2005266828A1 (de) |
CA (1) | CA2575283A1 (de) |
MX (1) | MX2007001074A (de) |
NO (1) | NO20070856L (de) |
RU (1) | RU2007103177A (de) |
WO (1) | WO2006010189A1 (de) |
ZA (1) | ZA200701438B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432532A (zh) * | 2011-11-10 | 2012-05-02 | 天津市汉康医药生物技术有限公司 | 高纯度托拉塞米化合物 |
CN104370805A (zh) * | 2013-08-13 | 2015-02-25 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212537A1 (de) * | 1985-08-17 | 1987-03-04 | Roche Diagnostics GmbH | Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid |
US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
WO2001010441A1 (en) * | 1999-08-11 | 2001-02-15 | Teva Pharmaceutical Industries Ltd. | Torsemide polymorphs |
-
2004
- 2004-07-28 AT AT0129304A patent/AT500576B1/de active
-
2005
- 2005-07-28 ZA ZA200701438A patent/ZA200701438B/en unknown
- 2005-07-28 AU AU2005266828A patent/AU2005266828A1/en not_active Abandoned
- 2005-07-28 EP EP05763057A patent/EP1773778A1/de not_active Withdrawn
- 2005-07-28 CN CNA2005800252020A patent/CN101056856A/zh active Pending
- 2005-07-28 WO PCT/AT2005/000299 patent/WO2006010189A1/de active Application Filing
- 2005-07-28 MX MX2007001074A patent/MX2007001074A/es not_active Application Discontinuation
- 2005-07-28 US US11/658,514 patent/US20070260068A1/en not_active Abandoned
- 2005-07-28 JP JP2007522871A patent/JP2008507568A/ja active Pending
- 2005-07-28 CA CA002575283A patent/CA2575283A1/en not_active Abandoned
- 2005-07-28 RU RU2007103177/04A patent/RU2007103177A/ru not_active Application Discontinuation
-
2007
- 2007-02-14 NO NO20070856A patent/NO20070856L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212537A1 (de) * | 1985-08-17 | 1987-03-04 | Roche Diagnostics GmbH | Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid |
US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
WO2001010441A1 (en) * | 1999-08-11 | 2001-02-15 | Teva Pharmaceutical Industries Ltd. | Torsemide polymorphs |
Non-Patent Citations (1)
Title |
---|
ROLLINGER, JUDITH MARIA ET AL: "Crystal forms of torasemide: new insights", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS , 53(1), 75-86 CODEN: EJPBEL; ISSN: 0939-6411, 2002, XP009056000 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432532A (zh) * | 2011-11-10 | 2012-05-02 | 天津市汉康医药生物技术有限公司 | 高纯度托拉塞米化合物 |
CN104370805A (zh) * | 2013-08-13 | 2015-02-25 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
Also Published As
Publication number | Publication date |
---|---|
JP2008507568A (ja) | 2008-03-13 |
ZA200701438B (en) | 2008-06-25 |
CA2575283A1 (en) | 2006-02-02 |
AT500576A1 (de) | 2006-02-15 |
RU2007103177A (ru) | 2008-08-10 |
AT500576B1 (de) | 2006-11-15 |
US20070260068A1 (en) | 2007-11-08 |
NO20070856L (no) | 2006-04-19 |
EP1773778A1 (de) | 2007-04-18 |
CN101056856A (zh) | 2007-10-17 |
MX2007001074A (es) | 2007-04-19 |
AU2005266828A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3529529C2 (de) | ||
EP1660482B1 (de) | 3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel | |
DE202018006384U1 (de) | Herstellung von Psilocybin, verschiedenen polymorphen Formen, Zwischenprodukten, Formulierungen und deren Verwendung | |
DE29924789U1 (de) | Neue Kristallmodifikation N von Torasemid | |
WO2006010189A1 (de) | Verfahren zur reindarstellungvon kristallformen von torsemid | |
DE2141818A1 (de) | 2-phenylimino-imidazolidine, deren saeureadditionssalze und verfahren zu deren herstellung | |
WO1998047872A1 (de) | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a | |
DE60131416T2 (de) | Chirale fluochinolon-argininsalzformen | |
WO2011067236A2 (de) | Raltegravir-polymorphe | |
DE69917282T2 (de) | Verfahren zur herstellung von zofenopril-calciumsalz | |
EP2293856B1 (de) | Anordnung und verfahren zur herstellung von hochreinen kristallen | |
DE69907467T2 (de) | Verfahren zur herstellung von einer nicht-kristallinen wasswerfreien form von paroxetin hydrochlorid | |
EP1517731B1 (de) | Verfahren zur herstellung einer spezifischen kristallmodifikation von 2-(2-chlor-4-mesyl-benzoyl)-cyclohexan-1,3-dion | |
DE3523686C2 (de) | ||
EP1313745A1 (de) | Amifostin-monohydrat und verfahren zu seiner herstellung | |
WO2006000422A1 (de) | Verfahren zur herstellung von lagerstabiler mafosfamid-lysin-salz lyophilisat bulkware | |
DE3710177A1 (de) | Calciumlactat-glycerin-addukt, verfahren zu seiner herstellung sowie seine verwendung | |
EP1221438A2 (de) | Salze von Amlodipin-Mesylat | |
EP2326322B1 (de) | Neue kristallform von calcium-3-acetylaminopropan-1-sulfonat | |
DE1493504A1 (de) | Verfahren zur Herstellung von 2-Aminoalkyl-Schwefelsaeureestern | |
EP3149014B1 (de) | Verfahren zur herstellung kristalliner dtpmp | |
DE566136C (de) | Verfahren zur Herstellung eines Dinatriumphosphats mit 2 Molekuelen Kristallwasser | |
DE3906267A1 (de) | Pyridylcarboxyl-isosorbid-derivat | |
WO2013037731A1 (de) | Neue polymorphe form von raltegravir-kalium | |
DE112010004862T5 (de) | Polymorphe Form von Nevirapin und deren Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005763057 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 552848 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001074 Country of ref document: MX Ref document number: 2007103177 Country of ref document: RU Ref document number: 200580025202.0 Country of ref document: CN Ref document number: 2575283 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007522871 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005266828 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/01438 Country of ref document: ZA Ref document number: 200701438 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005266828 Country of ref document: AU Date of ref document: 20050728 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005266828 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11658514 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763057 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11658514 Country of ref document: US |